The Trump Administration has finalized its plans aimed at lowering drug prices within Medicare, notably through the introduction of the most-favored nation pricing model for Part B drugs. However, the initiative has faced scrutiny, with reports indicating that the proposed savings have significantly decreased from initial estimates of $11.9 billion to just $440 million. Critics highlight that the new model may only apply to a limited number of companies due to exemptions, raising concerns about its overall effectiveness. Additionally, the CMS has rolled out a new payment model for Medicaid, seeking to benchmark U.S. drug prices against those in Australia and 18 other countries, although the healthcare industry has noted a reduced scope and presence during discussions. As the GLOBE model is finalized, stakeholders are left to contemplate the broader implications for affordability and access to medications.